Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...

Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared with the U.S ...

Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...

The FDA expands Palynziq approval to include pediatric patients aged 12 years and older with phenylketonuria and uncontrolled blood Phe levels.

People with chronic back pain process everyday sounds differently, and more intensely, than people without pain, according to new research from the University of Colorado Anschutz. Published today in ...

Background Little is known about the association between direct pollen exposure and cognitive performance. The aim of our ...

Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the ...

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026 ...

Phase 3 PEACE trial data support the accelerated approval of Loargys for the treatment of arginase 1 deficiency in pediatric and adult patients.

Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization ...